Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Conversation - Cervarix, February 26, 2008

Record of Communication

STN Number: 125259/0
Manufacturer: GlaxoSmithKline Biologicals
Product: Human Papillomavirus Vaccine, ASO4 Adjuvant-Adsorbed

To: Matt Whitman
From: Helen S. Gemignani, Regulatory Project Manager
Subject: Request for Clarification RE: Thrombocytopenia
Date: 26-Feb-2008
Time: 12:28 pm
Contact Phone: 610 787-3726


We have requests for clarification in regard to the document entitled "24 Oct 2007 IR request_table_14 Dec 2007.doc", and in particular, to the -b(4)- BB-IND ------b(4)---- treatment arm entries on page 2 of the document.

  1. Please clarify that there was only one patient who had thromboctyopenia and one patient who had diabetes mellitus.
  2. Please clarify whether there are source documents available for either of these cases and submit them for our review.
  3. Please confirm that there are no other cases of thrombocytopenia reported to BBIND -b(4)- in a --b(4)-- treatment arm.

Please submit your responses as an amendment to the BLA.

Page Last Updated: 04/14/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English